UNSPSC 51384521: Dexibuprofen lysine

This classification denotes an ibuprofen analog and nonsteroidal anti-inflammatory agent C13H18O2.C6H14N2O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T179MT9211, chemically known as benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-, (s)-, compd. with l-lysine (1:1) monohydrate, but more generally known as dexibuprofen lysine, which bears US NIH Compound Identifier 15009331. Most nations, for tariff and trade purposes, schedule dexibuprofen lysine under HS 29163900 and SITC 51379.

As of Q4 2014, DEXIBUPROFEN LYSINE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H](C1CCC(CC1)CC(C)C)C(=O)O.C(CCN)C[C@@H](C(=O)O)N.O.

UNSPSC 51384521 Dexibuprofen lysine is a Commodity code that in recent state and local procurement activity represents pharmaceutical products—primarily naloxone, generic multi-source pharmaceuticals, and over-the-counter products—procured by health departments, cooperative purchasing alliances, and state health agencies to support community health initiatives and pharmacy benefit programs. State and local governments under this code are buying finished pharmaceutical products for distribution through established supply chains, with emphasis on compliance with Good Manufacturing Practices, Drug Supply Chain Security Act standards, and federal pharmaceutical regulations. Issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating state and local facilities including Oregon).

Recent activity shows geographic spread across Florida, Texas, and Minnesota, with multi-state reach through cooperative purchasing vehicles. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida; Texas HHS's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs to establish therapeutic pharmacy initiatives outside traditional pharmacy benefit manager channels; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with awards effective July 1, 2026. The MMCAP procurement applies a 3 percent administrative fee structure and weighted evaluation prioritizing price competitiveness at 75 percent, with contract terms of two years for new vendors. All three opportunities require vendors to maintain specific insurance coverage, comply with E-Verify and federal environmental regulations where applicable, and demonstrate manufacturing and supply-chain compliance documentation.